IP Library › Granted Patent US 11,920,138
Granted Patent B2
US 11,920,138 · App. 16/507,977 · Granted Mar 5, 2024

Fusion proteins and methods thereof

Inventors: Antonio Iavarone (New York, NY); Anna Lasorella (New York, NY); Raul Rabadan (New York, NY)
Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
C12N15/62C07K14/47C07K14/71C07K14/82C07K16/18C07K16/2863C12N9/12C12Q1/6886G01N33/57492C07K2319/00C07K2319/73C12Q2600/158G01N2333/91205
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,920,138
App. No.
16/507,977
Granted
Mar 5, 2024
Kind
B2
Abstract

The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Claims (26)

1. A synthetic polynucleotide comprising a polynucleotide sequence complementary to a portion of a polynucleotide sequence encoding a breakpoint between a FGFR1 portion and a TACC1 portion of a FGFR1-TACC1 fusion protein or a complement thereof, or a breakpoint between a FGFR3 portion and a TACC3 portion of a FGFR3-TACC3 fusion protein or a complement thereof, wherein the synthetic polynucleotide further comprises a chemical modification, wherein the chemical modification comprises a radioactive molecule, a fluorescent molecule, a chemiluminescent molecule, an enzyme, or an affinity molecule.

2. The synthetic polynucleotide of claim 1 , wherein the synthetic polynucleotide is between 10 and 30 nucleotides long.

3. The synthetic polynucleotide of claim 1 , wherein the chemical modification comprises a fluorescent molecule.

4. The synthetic polynucleotide of claim 3 , wherein the synthetic polynucleotide is between 10 and 30 nucleotides long.

5. The synthetic polynucleotide of claim 1 , wherein the polynucleotide sequence is complementary to the portion of the polynucleotide sequence encoding the breakpoint between the FGFR3 portion and the TACC3 portion of the FGFR3-TACC3 fusion protein, or a complement thereof.

6. The synthetic polypeptide of claim 5 , wherein a polynucleotide sequence encoding the FGFR3-TACC3 fusion protein comprises a tyrosine kinase domain of the FGFR3 portion fused to a TACC domain of the TACC3 portion.

7. The synthetic polynucleotide of claim 6 , wherein the breakpoint between the FGFR3 portion and the TACC3 portion of the FGFR3-TACC3 fusion protein comprises SEQ ID NO: 85, 86, 87, or 89.

8. The synthetic polynucleotide of claim 6 , wherein the synthetic polynucleotide sequence comprises SEQ ID NO: 80, 81, 82, or 84, or a complement thereof.

9. The synthetic polynucleotide of claim 1 , wherein the polynucleotide sequence is complementary to the portion of a polynucleotide sequence encoding the breakpoint between the FGFR1 portion and the TACC1 portion of the FGFR1-TACC1 fusion protein, or a complement thereof.

10. The synthetic polypeptide of claim 9 , wherein a polynucleotide sequence encoding the FGFR1-TACC1 fusion protein comprises a tyrosine kinase domain of the FGFR1 portion fused to a TACC domain of the TACC1 portion.

11. The synthetic polynucleotide of claim 10 , wherein the breakpoint between the FGFR1 portion and the TACC1 portion of the FGFR1-TACC1 fusion protein comprises SEQ ID NO: 88.

12. The synthetic polynucleotide of claim 10 , wherein the synthetic polynucleotide sequence comprises SEQ ID NO: 83, or a complement thereof.

13. The synthetic polynucleotide of claim 6 , wherein the chemical modification comprises a fluorescent molecule.

14. The synthetic polynucleotide of claim 10 , wherein the chemical modification comprises a fluorescent molecule.

15. The synthetic polynucleotide of claim 7 , wherein the chemical modification comprises a fluorescent molecule.

16. The synthetic polynucleotide of claim 8 , wherein the chemical modification comprises a fluorescent molecule.

17. The synthetic polynucleotide of claim 11 , wherein the chemical modification comprises a fluorescent molecule.

18. The synthetic polynucleotide of claim 12 , wherein the chemical modification comprises a fluorescent molecule.

19. The synthetic polynucleotide of claim 6 , wherein the synthetic polynucleotide is between 10 and 30 nucleotides long.

20. The synthetic polynucleotide of claim 10 , wherein the synthetic polynucleotide is between 10 and 30 nucleotides long.

21. The synthetic polynucleotide of claim 7 , wherein the synthetic polynucleotide is between 10 and 30 nucleotides long.

22. The synthetic polynucleotide of claim 11 , wherein the synthetic polynucleotide is between 10 and 30 nucleotides long.

23. The synthetic polynucleotide of claim 13 , wherein the synthetic polynucleotide is between 10 and 30 nucleotides long.

24. The synthetic polynucleotide of claim 14 , wherein the synthetic polynucleotide is between 10 and 30 nucleotides long.

25. The synthetic polynucleotide of claim 13 , wherein the fluorescent molecule is capable of being detected during an amplification reaction.

26. The synthetic polynucleotide of claim 25 , wherein the amplification reaction is RT-PCR.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE THIRD ASSIGNOR'S EXECUTION DATE PREVIOUSLY RECORDED AT REEL: 049835 FRAME: 0354. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 26, 2019
From: IAVARONE, ANTONIO; LASORELLA, ANNA; RABADAN, RAUL
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 049879/0597 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2019
From: IAVARONE, ANTONIO; LASORELLA, ANNA; RABADAN, RAUL
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 049835/0354 →
Continuity (5)
Continuation 14604530 · Jan 23, 2015
Continuation In Part PCTUS2013051888 · Jul 24, 2013
Provisional Application 62096311 · Dec 23, 2014
Provisional Application 61675006 · Jul 24, 2012
Related Publication 20200033353A1 · Jan 30, 2020